ストックスクリーナーアプリを入手
11.98
1.24%
-0.15
アフターアワーズ：
12.03
0.05
+0.42%
前日終値:
$12.13
開ける：
$12.35
24時間の取引高:
351.78K
Relative Volume:
0.70
時価総額：
$317.77M
収益：
-
当期純損益:
$-52.60M
株価収益率:
-8.9664
EPS:
-1.3361
ネットキャッシュフロー:
$-35.80M
1週間 パフォーマンス:
+4.40%
1か月 パフォーマンス:
-16.22%
6か月 パフォーマンス:
+26.50%
1年 パフォーマンス:
+98.06%
1日の値動き範囲:
$11.95
$12.45
1週間の範囲:
$11.51
$12.75
52週間の値動き範囲:
$5.34
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
名前
Tenax Therapeutics Inc
セクター
電話
919-855-2100
住所
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
11.98 | 321.75M | 0 | -52.60M | -35.80M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 開始されました | Piper Sandler | Overweight |
| 2024-10-24 | 開始されました | Leerink Partners | Outperform |
| 2024-10-14 | 開始されました | Guggenheim | Buy |
| 2024-09-30 | 開始されました | William Blair | Outperform |
| 2017-05-18 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 開始されました | MLV & Co | Buy |
| 2014-11-18 | 開始されました | WallachBeth | Buy |
すべてを表示
Tenax Therapeutics Inc (TENX) 最新ニュース
Tenax Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Clinical DevelopmentEarnings Call Q&A - Newser
Tenax Therapeutics (TENX) Faces Resistance Test After 1.86% Pullback From Recent HighsShared Trade Alerts - Newser
What's Driving Tenax Therapeutics' Recent Surge - Kavout
Millennium Group (TENX) reports 1,347,130 shared votes, 5.1% stake - Stock Titan
Tectonic Therapeutics: Currently In A Catalyst Vacuum (NASDAQ:TECX) - Seeking Alpha
Understanding Momentum Shifts in (TENX) - Stock Traders Daily
LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Stonepine holds 975,200 shares in Tenax Therapeutics (NASDAQ: TENX), 3.7% stake - Stock Titan
VHCP group discloses 9.99% stake in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
Point72 group discloses 533,965 shares in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
BVF affiliates hold warrants convertible into TENX shares (NASDAQ: TENX) constrained by 9.99% blocker - Stock Titan
Perceptive Advisors (NASDAQ: TENX) reports 1.45M-share position - Stock Titan
About Us - FinancialContent
Tenax Therapeutics (TENX) Stock: Consolidating at $$11.93 — Next Move Ahead 2026-05-15Insider Buying - Newser
Dellora holds ~394,665 shares in TENX (Nasdaq: TENX) per amended 13G/A - Stock Titan
RTW Investments (TENX) reports 9.99% stake in Tenax Therapeutics - Stock Titan
Tenax Therapeutics (TENX) Stalls at $$11.94 — Consolidation Phase 2026-05-14Growth Factor - Newser
Tenax Therapeutics (NASDAQ: TENX) awards CFO 10K shares and 450K options - Stock Titan
TENAX THERAPEUTICS (TENX) CFO files Form 3 showing zero Common Stock owned - Stock Titan
Phase 3 spending lifts Tenax (NASDAQ: TENX) Q1 loss but extends runway - Stock Titan
TradingKey - TradingKey
Tenax Therapeutics Announces Q1 2026 Results, Advances Phase 3 LEVEL Study for TNX-103 and Expands Leadership Team - Minichart
Tenax Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
A Look at Tenax Therapeutics (TENX) Valuation After Q1 2026: EPS - GuruFocus
Tenax Therapeutics (TENX) Shares Updates on TNX-103 Phase 3 Stud - GuruFocus
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
Tenax Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tenax Therapeutics (NASDAQ:TENX) Q1 2026 Slightly Beats EPS, Gears Up for Pivotal Phase 3 Data in Q3 - ChartMill
Tenax Therapeutics (NASDAQ: TENX) boosts Phase 3 spend, extends cash runway - Stock Titan
TENAX THERAPEUTICS ($TENX) Releases Q1 2026 Earnings - Quiver Quantitative
Tenax Therapeutics: Q1 Earnings Snapshot - Barchart.com
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
William Blair Maintains Tenax Therapeutics(TENX.US) With Buy Rating - Moomoo
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | TENX Stock News - GuruFocus
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Tenax uses stock options to hire 4 staff in clinical and commercial roles - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Weekly Voice
Avoiding Lag: Real-Time Signals in (TENX) Movement - Stock Traders Daily
T. Rowe Price (TENX) reports 2.84M shares, 11.0% stake in Tenax - Stock Titan
T. Rowe Price (NASDAQ: TENX) holds 2.95M shares, 17.2% disclosed - Stock Titan
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
TENX SEC FilingsTenax Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Tenax Therapeutics names Timothy Healey as chief commercial officer By Investing.com - Investing.com Australia
Invus affiliates disclose 2.1% stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer - Investing News Network
Tenax Therapeutics names Timothy Healey as chief commercial officer - Investing.com
Tenax brings in drug launch veteran Timothy Healey to prep TNX-103 - Stock Titan
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics Inc (TENX) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):